Clinical Correlation and Role of Cyclin D1 Expression in Glioblastoma Patients: A Study From North India

Abstract

Background/Aims Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor. Cyclin D1 is a protein that in humans is encoded by the CCND1 gene. Cyclin D1 protein is frequently overexpressed in malignant gliomas. Methods It is an observational study comprising 40 biopsy-proven cases of GBM in a span of one and half years. Immunohistochemistry (IHC) was used with Cyclin D1 monoclonal antibody. Cyclin D1 on the outcome was assessed using the Kaplan-Meier survival estimate and compared by log-rank test. Results Cyclin D1 was expressed in 60% of patients. The majority (72.5%) of patients expired during the study period, out of which 69% showed immune-expression in contrast to living subjects, out of which only 45.5% of patients exhibited expression. The maximum number of glioblastoma patients were aged between 41 and 50 years (40%), followed by those aged between 31 and 40 years (20%). The male to female ratio of study subjects was 3.44:1. Conclusion The study concluded that there is no significant association between Cyclin D1 expression status and different demographic, clinical, and outcome variables.

Role of Nucleobindin-2 in the Clinical Pathogenesis and Treatment Resistance of Glioblastoma

“…Cyclin D1 binds to cyclin-dependent kinase 4 and 6, activating the G1/S transition. High expression of Cyclin D1 is associated with the pathological grade and proliferative activity of astrocytomas [27,28]. Overexpression of Cyclin D1 induces TMZ resistance by upregulating P-gp in human malignant glioma cells.…”

Enquire Reconstructs and Expands Context-Specific Co-Occurrence Networks From Biomedical Literature

“…Also, the proposed cancer-related case studies consistently enrich a small cluster of oncology-related pathways like Aberrant regulations of the mitotic cell cycle (R-HSA-9687139 and its sub-pathways). Interestingly, a set of pathways linked to cell cycle like Cyclin D associated events in G1 (R-HSA-69231) are enriched in the oligodendrocyte case study and reported to be also relevant in glioblastoma (53)(54)(55)(56). We included a positive control case study as we expected that a co-occurrence network derived from a highly heterogenous corpus should possess little context specificity.…”

“…Similarly, some of Chromatin Organization and Developmental Biology pathways are almost exclusively enriched in the networks corresponding to oligodendrocyte differentiation. Interestingly, a set of pathways linked to cell cycle like Cyclin D associated events in G1 (R-HSA-69231) are enriched in the oligodendrocyte case study and reported to be also relevant in glioblastoma [41][42][43][44] . All case studies appear constitutively enriched in a cluster of Pathways in Cancer annotated downstream of Diseases of signal transduction by growth factor receptors and second messengers (R-HSA-5663202).…”